Case Type: Mergers & Acquisitions

NantKwest, Inc. (NK) relating to its proposed merger with ImmunityBio. Under the terms of the agreement, ImmunityBio shareholders will receive 0.8190 shares of NatKwest per share they own.

New Providence Acquisition Corp. (NPA) relating to its proposed reverse merger with AST & Science LLC (“AST”). Under the terms of the agreement, NPA will acquire AST through a reverse merger that will result in AST becoming a publicly traded company.

TPG Pace Beneficial Finance Corp. (TPGY) relating to its proposed reverse merger with EV Charged B.V. (“EVBox”). Under the terms of the agreement, TPGY will acquire EVBox through a reverse merger that will result in EVBox becoming a publicly traded company.

BioTelemetry, Inc. (BEAT) relating to its proposed acquisition by Royal Phillips. Under the terms of the agreement, BEAT shareholders will receive $72.00 in cash per share.

TCF Financial Corp. (TCF) relating to its proposed merger with Huntington Bancshares, Inc. Under the terms of the agreement, TCF shareholders will receive 3.0028 shares of Huntington per share they own.

Tottenham Acquisition I Limited (TOTA) relating to its proposed reverse merger with Clene Nanomedicine, Inc. Under the terms of the agreement, Tottenham will acquire Clene through a reverse merger that will result in Clene becoming a publicly traded company.

Prevail Therapeutics, Inc. (PRVL) relating to its proposed acquisition by Eli Lilly and Company. Under the terms of the agreement, Prevail shareholders will receive $22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to $4.00 per share.

Experience Investment Corp. (EXPC) relating to its proposed merger with BLADE Urban Air Mobility, Inc. Under the terms of the agreement, Experience will issue a number of shares to BLADE shareholders, who in turn will own approximately 43.2% of the combined company.

Cardtronics plc (CATM) relating to its proposed acquisition by affiliates of Apollo Global Management, Inc. and Hudson Executive Capital LP. Under the terms of the agreement, Cardtronics shareholders will receive $35.00 in cash per share.

Alexion Pharmaceuticals, Inc. (ALXN) relating to its proposed acquisition by AstraZeneca, PLC. Under the terms of the agreement, Alexion shareholders will receive 2.1243 shares of AstraZeneca and $60.00 in cash per share.